IXHL vs. AUPH, PLRX, LBPH, PAHC, ANAB, MLYS, NUVB, SAGE, DNTH, and RNAC
Should you be buying Incannex Healthcare stock or one of its competitors? The main competitors of Incannex Healthcare include Aurinia Pharmaceuticals (AUPH), Pliant Therapeutics (PLRX), Longboard Pharmaceuticals (LBPH), Phibro Animal Health (PAHC), AnaptysBio (ANAB), Mineralys Therapeutics (MLYS), Nuvation Bio (NUVB), Sage Therapeutics (SAGE), Dianthus Therapeutics (DNTH), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical preparations" industry.
Aurinia Pharmaceuticals (NASDAQ:AUPH) and Incannex Healthcare (NASDAQ:IXHL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, dividends and community ranking.
In the previous week, Aurinia Pharmaceuticals had 3 more articles in the media than Incannex Healthcare. MarketBeat recorded 3 mentions for Aurinia Pharmaceuticals and 0 mentions for Incannex Healthcare. Incannex Healthcare's average media sentiment score of 1.10 beat Aurinia Pharmaceuticals' score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.
Aurinia Pharmaceuticals received 567 more outperform votes than Incannex Healthcare when rated by MarketBeat users.
Aurinia Pharmaceuticals has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Incannex Healthcare has a beta of 8.36, meaning that its share price is 736% more volatile than the S&P 500.
Incannex Healthcare has lower revenue, but higher earnings than Aurinia Pharmaceuticals.
Incannex Healthcare has a net margin of 0.00% compared to Incannex Healthcare's net margin of -32.69%. Aurinia Pharmaceuticals' return on equity of 0.00% beat Incannex Healthcare's return on equity.
Aurinia Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 88.68%. Given Incannex Healthcare's higher probable upside, research analysts plainly believe Aurinia Pharmaceuticals is more favorable than Incannex Healthcare.
36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 0.4% of Incannex Healthcare shares are held by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 14.6% of Incannex Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Aurinia Pharmaceuticals and Incannex Healthcare tied by winning 7 of the 14 factors compared between the two stocks.
Get Incannex Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for IXHL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IXHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Incannex Healthcare Competitors List
Related Companies and Tools
